Key terms
About ALLR
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company operates in two geographic areas: Denmark and the United States. The company was founded on April 4, 2021 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALLR news
Apr 18
7:12am ET
Allarity Therapeutics Granted Extension for Nasdaq Compliance
Apr 17
9:11am ET
Allarity receives extension from Nasdaq to regain compliance
Apr 08
7:50pm ET
Allarity Therapeutics Inc trading halted, news pending
Apr 05
8:42am ET
Allarity Therapeutics Announces Upcoming Reverse Stock Split
Apr 04
9:26am ET
Allarity announces 1-for-20 reverse stock split
Apr 01
9:52am ET
Allarity Therapeutics Advances Precision Oncology with Stenoparib
Mar 27
8:35am ET
Allarity makes strategic pivot to focus solely on accelerating stenoparib
Mar 26
8:23am ET
Allarity Therapeutics Granted Extension for Nasdaq Compliance
Mar 25
7:48am ET
Allarity receives extension from Nasdaq Hearings Panel to regain compliance
Mar 08
8:52am ET
Allarity Therapeutics Issues Regulation FD Disclosure Notice
Mar 08
7:20am ET
Allarity expects to announce interim data from DRP-guided Phase 2 trial in Q2
Mar 08
7:18am ET
Allarity reports 2023 EPS ($10.26) vs. ($3,093.42) last year
Mar 04
4:25pm ET
Allarity Therapeutics Announces CMO Marie Foegh’s Departure
Mar 01
9:32am ET
Allarity Therapeutics Adjusts Convertible Notes and Updates Presentation
Jan 26
5:00am ET
Allarity Therapeutics Amends Securities Purchase Agreement with 3i
No recent press releases are available for ALLR
ALLR Financials
Key terms
Ad Feedback
ALLR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALLR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
